Astatine-211 based radionuclide therapy: Current clinical trial landscape

Area of Science:

• Nuclear medicine
• Radiopharmaceutical therapy
• Oncology

Background:

• Astatine-211 (²¹¹At) possesses advantageous physical characteristics for targeted alpha therapy (TAT).
• TAT utilizes alpha-emitting radionuclides to deliver high-energy radiation directly to cancer cells.
• ²¹¹At is a leading candidate radionuclide for clinical application in TAT.

Purpose of the Study:

• To review the clinical efficacy and safety of Astatine-211 in targeted alpha therapy.
• To provide an overview of completed and ongoing clinical trials involving ²¹¹At.
• To discuss the future potential and challenges of ²¹¹At-based TAT.

Main Methods:

• Systematic review of completed clinical trials.
• Analysis of data from ongoing clinical investigations.
• Discussion of preclinical and clinical research findings.

Main Results:

• Summary of key outcomes from completed ²¹¹At TAT clinical trials.
• Presentation of current progress and preliminary results from ongoing studies.
• Identification of therapeutic benefits and potential toxicities observed.

Conclusions:

• ²¹¹At demonstrates significant potential as a therapeutic radionuclide for targeted alpha therapy.
• Further clinical trials are essential to fully establish the role of ²¹¹At in cancer treatment.
• Ongoing research and development are crucial for optimizing ²¹¹At-based therapies.